AAP 2023 Pediatric Obesity Guidelines: A Parent's Plain-Language Summary

The AAP 2023 obesity guidelines are the American Academy of Pediatrics' first comprehensive Clinical Practice Guideline for the evaluation and treatment of children and teens with obesity, published in January 2023. The guideline recommends regular BMI screening from age 2, intensive lifestyle treatment as the foundation, weight-loss medication offered for consideration for adolescents 12 and older who meet criteria, and a surgery-evaluation referral for adolescents 13 and older with severe obesity. This page explains each part in plain language and links to the source.

What the AAP 2023 guideline actually says

The Clinical Practice Guideline (CPG) was published on January 9, 2023, in Pediatrics (Hampl SE et al., doi:10.1542/peds.2022-060640). It is the AAP's first comprehensive treatment guideline for pediatric obesity, building on evidence accumulated since the 2007 AAP Expert Committee report (Barlow SE et al., Pediatrics 2007).

Four themes organize the recommendations: (1) treat childhood obesity as a chronic condition that benefits from sustained care; (2) treat the whole child, not just the BMI number, including behavioral health, family-system care, and social factors; (3) intervene early once treatment is offered, rather than watchful waiting; (4) eliminate weight stigma from care delivery.

How the AAP defines overweight, obesity, and severe obesity

Direct answer: The CPG defines overweight as BMI in the 85th to under 95th percentile, obesity as BMI at or above the 95th percentile, and severe obesity as BMI at or above 120 percent of the 95th percentile for age and sex.

BMI percentile compares a child's BMI to a reference population of children the same age and sex on the CDC growth charts. A BMI at the 95th percentile means the child's BMI is higher than 95 percent of children the same age and sex.

Verbatim from KAS 1:

"Pediatricians and other PHCPs should measure height and weight, calculate BMI, and assess BMI percentile using age- and sex-specific CDC growth charts or growth charts for children with severe obesity at least annually for all children 2 to 18 years of age to screen for overweight (BMI ≥85th percentile to <95th percentile), obesity (BMI ≥95th percentile), and severe obesity (BMI ≥120% of the 95th percentile for age and sex)."

Severe obesity has two classes. Class 2 is a BMI of 120 to under 140 percent of the 95th percentile, or 35 to under 39 kg/m², whichever is lower for age and sex. Class 3 is a BMI at or above 140 percent of the 95th percentile, or at or above 40 kg/m², whichever is lower. Severe obesity is defined by BMI alone; the CPG does not require any specific comorbidity.

IHBLT: intensive lifestyle treatment is the foundation

Direct answer: The CPG recommends IHBLT as first-line treatment for children 6 and older with overweight or obesity, with 26 or more hours of contact over 3 to 12 months for the most effective effect.

IHBLT stands for Intensive Health Behavior and Lifestyle Treatment: structured, family-centered programs that combine nutrition counseling, physical-activity support, behavioral skills, and parent engagement. The CPG recommends 26 or more hours of contact time over 3 to 12 months, the threshold the evidence base associates with meaningfully better and more durable BMI reduction. KAS 11, verbatim:

"Pediatricians and other PHCPs should provide or refer children 6 years and older (Grade B) and may provide or refer children 2 through 5 years of age (Grade C) with overweight (BMI ≥85th percentile to <95th percentile) and obesity (BMI ≥95th percentile) to intensive health behavior and lifestyle treatment. Health behavior and lifestyle treatment is more effective with greater contact hours; the most effective treatment includes 26 or more hours of face-to-face, family-based, multicomponent treatment over a 3- to 12-month period."

The 26-hour figure comes from a systematic review the CPG cites (O'Connor EA et al., JAMA 2017). Programs reaching 26 or more hours produced meaningful BMI reduction with maintenance; shorter programs did not. The 2024 USPSTF statement (Nicholson WK et al., JAMA 2024) confirmed the same standard.

IHBLT is the base layer under every other recommendation. Pharmacotherapy and surgery, where they apply, are offered as adjuncts to IHBLT, not as replacements.

When the AAP recommends considering medication

Direct answer: The CPG recommends offering weight-loss pharmacotherapy to adolescents 12 and older with obesity (BMI at or above the 95th percentile), as an adjunct to lifestyle treatment, with attention to each medication's indications, risks, and benefits, and with shared decision-making.

KAS 12, verbatim:

"Pediatricians and other PHCPs should offer adolescents 12 years and older with obesity (BMI ≥95th percentile) weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment."

Two clarifications often get lost. First, the recommendation is to offer the consideration, not to prescribe automatically. Second, the eligibility threshold is age and BMI, not a specific comorbidity. KAS 12 applies to adolescents 12 and older with obesity. The CPG directs clinicians to evaluate and treat obesity-related conditions (type 2 diabetes, high blood pressure, dyslipidemia, fatty liver, sleep apnea, and others) alongside pharmacotherapy, not as a precondition for it.

The evidence base includes the STEP TEENS trial of once-weekly semaglutide (Weghuber D et al., NEJM 2022). In that trial, 201 adolescents ages 12 to under 18 with obesity were treated for 68 weeks; adolescents who received once-weekly semaglutide alongside behavioral lifestyle support reduced their BMI by an average of 16.1 percent, while those who received placebo with the same lifestyle support increased BMI by 0.6 percent. Other medications referenced in the CPG include metformin, phentermine-topiramate, liraglutide, and orlistat. Each has its own FDA-approved age, indication, risks, and benefits.

When the AAP recommends a surgery-evaluation referral

Direct answer: For adolescents 13 and older with severe obesity, the CPG recommends offering a referral to a comprehensive pediatric metabolic and bariatric surgery center for evaluation. The recommendation is for a referral to be evaluated, not for surgery itself.

KAS 13, verbatim (excerpt):

"...adolescents 13 years and older with severe obesity (BMI ≥120% of the 95th percentile for age and sex) for evaluation for metabolic and bariatric surgery..."

The recommendation is precise: it is a referral to a comprehensive center, not a recommendation to operate. A multidisciplinary team evaluates whether surgery is the right next step over months, considering medical, nutritional, behavioral-health, and family components. Severe obesity here is defined by BMI alone (Class 2 or Class 3), not by comorbidity.

The evidence base includes the Teen-LABS cohort (Inge TH et al., NEJM 2016 and 2019). At 3 years post-surgery, weight reduction averaged about 27 percent and remission rates were high for type 2 diabetes (95 percent), prediabetes (76 percent), and elevated blood pressure (74 percent). At 5 years, adolescents undergoing gastric bypass had better remission rates than adults for type 2 diabetes (86 vs 53 percent) and high blood pressure (68 vs 41 percent). Teen-LABS also documented higher rates of micronutrient deficiencies in adolescents. The 5-year remission figures cited above come specifically from Roux-en-Y gastric bypass (Inge et al., NEJM 2019). The two current standard adolescent procedures are laparoscopic Roux-en-Y gastric bypass and vertical sleeve gastrectomy; both have strong long-term Teen-LABS durability data. Surgery is a serious decision, and the CPG recommendation reflects that: a referral to a center that can support the family through evaluation.

What the AAP names as foundational: equity, stigma, and mental-health screening

Direct answer: The CPG names equity, weight stigma, and mental-health screening (including disordered-eating screening) as foundational to obesity care, not as optional add-ons. The guideline is built on a family-centered, non-stigmatizing approach.

KAS 9, verbatim:

"Pediatricians and other PHCPs should treat overweight (BMI ≥85th percentile to <95th percentile) and obesity (BMI ≥95th percentile) in children and adolescents, following the principles of the medical home and the chronic care model, using a family-centered and nonstigmatizing approach that acknowledges obesity's biologic, social, and structural drivers."

The CPG names mental-health screening, including for depression, anxiety, and disordered eating, as part of routine obesity evaluation. It addresses the concern that intensive treatment could increase eating-disorder risk by recommending screening and care, not deferred treatment. The CPG also instructs clinicians to use person-first language and engage families as partners.

Common parent concerns about the 2023 rollout (over-medicalization, age thresholds, surgery in adolescents, stigma, eating-disorder risk) are not unaddressed in the guideline. They are named explicitly, and the recommendations sit on top of that foundation.

How the 2023 guideline differs from the 2007 recommendations

Direct answer: The 2023 CPG replaces the 2007 expert committee recommendations, which used a stepped-care, watchful-waiting model. The 2023 guideline recommends evaluating and intervening earlier.

The 2007 framework (Barlow SE; Expert Committee; Pediatrics 2007) used a Stage 1 to Stage 4 stepped-care model that progressed only after a defined trial at each prior stage. The 2023 CPG moves away from watchful waiting and recommends evaluation and treatment offers as soon as a child meets criteria, with intensity tailored to BMI category, age, and clinical picture. The CPG has not been substantively revised; a January 2024 Statement of Correction (Pediatrics 2024;153(1):e2023064612) updated one bibliographic reference only, leaving every Key Action Statement intact.

How Blueberry Balance implements the AAP framework

Direct answer: Blueberry Balance is one operational implementation of the AAP framework, built around the IHBLT base layer with DABOM-led specialist evaluation, and stepped-care pharmacotherapy consideration when indicated. Balance refers to comprehensive in-person centers for surgery evaluation.

The Balance protocol maps onto the AAP recommendations. The unlimited-coaching IHBLT base layer is designed to meet or exceed the 26-hour intensity bar from KAS 11. A DABOM-credentialed pediatrician leads the medical evaluation and, when indicated, the pharmacotherapy conversation under KAS 12. Balance does not perform surgery; when a KAS 13 surgery-evaluation referral is clinically appropriate, Balance's role is to support it. Balance is a pediatric obesity medicine specialty layer that works alongside the child's existing pediatrician.

Frequently asked questions

Does the AAP recommend Wegovy for 12-year-olds?

The 2023 guideline recommends offering weight-loss pharmacotherapy consideration to adolescents 12 and older with obesity (BMI at or above the 95th percentile), as an adjunct to lifestyle treatment, according to each medication's indications, risks, and benefits. The CPG does not name a single medication by brand. Wegovy (semaglutide) is one option in this class, supported by the STEP TEENS trial (Weghuber 2022); whether it is right for a particular adolescent depends on clinical evaluation and shared decision-making.

Does the AAP recommend weight-loss surgery for 13-year-olds?

The 2023 guideline recommends a referral for evaluation, not surgery itself. For adolescents 13 and older with severe obesity (BMI at or above 120 percent of the 95th percentile for age and sex), the CPG recommends offering a referral to a comprehensive pediatric metabolic and bariatric surgery center, where a multidisciplinary team determines whether surgery is the right next step. Most referred adolescents do not proceed straight to surgery; the evaluation itself runs for months.

Did the AAP retract or revise the 2023 guideline?

No. The CPG has not been retracted or substantively revised. A single Statement of Correction was published in January 2024 that updated one bibliographic reference (#505) only. No recommendation language was changed and no Key Action Statement was modified.

How does the AAP guideline address eating-disorder risk?

The CPG names disordered-eating screening as part of routine obesity evaluation. The guideline addresses the concern that intensive treatment could increase eating-disorder risk by recommending screening for and addressing those risks within care, not deferring treatment. It also instructs clinicians to use person-first language and a family-centered, non-stigmatizing approach.

Is Blueberry Balance an AAP-recommended program?

The AAP does not endorse specific programs. Balance is one operational implementation of the AAP framework. The Balance protocol is built around the IHBLT base layer described in KAS 11, with DABOM-led specialist evaluation and stepped-care pharmacotherapy consideration where it is clinically appropriate.

Does the AAP still recommend watchful waiting?

No. The 2023 guideline replaces the 2007 stepped-care, watchful-waiting model. KAS 11 recommends that clinicians provide or refer to intensive lifestyle treatment for children 6 and older with obesity once they meet criteria, rather than waiting through staged trials to escalate.

Where can I read the full AAP guideline myself?

The official Clinical Practice Guideline is published in Pediatrics (Hampl SE et al., 2023, doi:10.1542/peds.2022-060640) and the AAP also publishes a Summary of Key Action Statements PDF. Both are linked in the Sources section below. This page summarizes and explains the guideline in plain language; it is not the official guideline and is not a substitute for reading the primary source.

Next steps

If you want a pediatric obesity medicine specialist to help you and your teen apply the AAP framework, start a Blueberry Balance visit. Balance works alongside your child's existing pediatrician; our team is led by board-certified pediatricians with DABOM credentialing, and the protocol maps directly to the framework above.

Sources

• Hampl SE, Hassink SG, Skinner AC, Fox CK, Joseph PR, Jordan T, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640. Full text.
• Statement of Correction: Obesity Clinical Practice Guideline. Pediatrics. 2024;153(1):e2023064612.
• US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Interventions for High Body Mass Index in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;332(3):226 to 232. doi:10.1001/jama.2024.11146.
• O'Connor EA, Evans CV, Burda BU, Walsh ES, Eder M, Lozano P. Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017;317(23):2427 to 2444.
• Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245 to 2257. doi:10.1056/NEJMoa2208601.
• Inge TH, Courcoulas AP, Jenkins TM, et al. Weight Loss and Health Status 3 Years after Bariatric Surgery in Adolescents. N Engl J Med. 2016;374(2):113 to 123.
• Inge TH, Courcoulas AP, Jenkins TM, et al. Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults. N Engl J Med. 2019;380(22):2136 to 2145.
• Barlow SE; Expert Committee. Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report. Pediatrics. 2007;120(Suppl 4):S164 to S192.
• American Academy of Pediatrics. Summary of Key Action Statements (PDF).